Ann: CUV Appendix 4D Half Year Report, page-19

Result was solid. Perhaps some were hoping for more or a surprise? Sounds like the chair is a tad distracted at present with his own company. Perhaps he will step aside and allow another board member to replace him as chair. Lots of trials about to start but unfortunately no real substantial income on the horizon - I don’t think the sunscreen will be huge. A systemic melanogenic cream on the other hand would be very interesting . Lot’s of publicity around skin cancer in Oz right now. Hopefully they can expand the EPP market until the ACTH product launches. No rush for investors at this point. Perhaps another 12 months to wait - again!! GLTA